Wegener's granulomatosis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004427:Ear Diseases / Q000209:etiology; D005128:Eye Diseases / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D014890:Granulomatosis with Polyangiitis / Q000175:diagnosis; D006331:Heart Diseases / Q000209:etiology; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D007165:Immunosuppression Therapy; D007223:Infant; D007674:Kidney Diseases / Q000209:etiology / Q000473:pathology; D007678:Kidney Glomerulus / Q000473:pathology; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009316:National Institutes of Health (U.S.); D009422:Nervous System Diseases / Q000209:etiology; D012140:Respiratory Tract Diseases / Q000209:etiology / Q000473:pathology; D012871:Skin Diseases / Q000209:etiology; D014481:United States
D003520:Cyclophosphamide; D001379:Azathioprine